Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Ascendis Pharma A (ASND) over the last 10 years, with Q4 2025 value amounting to $105.5 million.

  • Ascendis Pharma A's Accounts Payables rose 245.82% to $105.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $105.5 million, marking a year-over-year increase of 245.82%. This contributed to the annual value of $102.5 million for FY2025, which is 53.83% down from last year.
  • Ascendis Pharma A's Accounts Payables amounted to $105.5 million in Q4 2025, which was up 245.82% from $91.9 million recorded in Q3 2025.
  • Ascendis Pharma A's Accounts Payables' 5-year high stood at $141.1 million during Q1 2023, with a 5-year trough of $53.2 million in Q2 2021.
  • In the last 5 years, Ascendis Pharma A's Accounts Payables had a median value of $96.8 million in 2023 and averaged $96.1 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 16035.1% in 2021, then crashed by 3752.98% in 2024.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Accounts Payables stood at $68.0 million in 2021, then skyrocketed by 51.65% to $103.1 million in 2022, then dropped by 1.29% to $101.7 million in 2023, then grew by 1.24% to $103.0 million in 2024, then increased by 2.46% to $105.5 million in 2025.
  • Its last three reported values are $105.5 million in Q4 2025, $91.9 million for Q3 2025, and $106.1 million during Q2 2025.